Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Lepage C
Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,
Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,
Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Coriat R
Authors: Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R,
Keywords: Neuroendocrine carcinoma, ano-rectal tumor, surgery, radio-chemotherapy,
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Bernard V, Lombard-Bohas C, Goichot B, Rohmer V, Guimbaud R,
Keywords: pancreatic endocrine tumor, insulinoma, Everolimus, hypoglycemia,
Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Guimbaud R, Valentin T, Duffas J, Carrere N, Otal P,
Keywords: neuroendocrine, tumors, well-differentiated, follow-up, multidisciplinary, lost care,